{"nctId":"NCT01440101","briefTitle":"Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)","startDateStruct":{"date":"2010-11"},"conditions":["Multiple Sclerosis"],"count":106,"armGroups":[{"label":"Double-blind Natalizumab 300 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Natalizumab (BG00002)"]},{"label":"Double-blind Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Open-label Natalizumab","type":"EXPERIMENTAL","interventionNames":["Drug: Natalizumab (BG00002)"]}],"interventions":[{"name":"Natalizumab (BG00002)","otherNames":["Tysabri"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Part A\n\nKey Inclusion Criteria:\n\n* Must give written informed consent and any authorizations required by local law.\n* Must have a diagnosis of relapsing-remitting MS, as defined by the revised McDonald criteria 1 through 4 (Polman et al, 2005). All other possible neurologic diagnoses must have been reasonably excluded by means of laboratory and/or imaging studies, in the opinion of the Investigator.\n* Japanese men and women aged 18 to 65, inclusive, at the time of informed consent.\n* All male subjects and female subjects of childbearing potential must practice effective contraception during the study and be able to continue contraception for 12 weeks after their last dose of study treatment.\n* Must have an Expanded Disability Status Scale (EDSS) score between 0.0 and 6.0, inclusive.\n* Must have experienced at least 1 medically documented clinical exacerbation within 12 months of enrollment.\n* Must be willing to remain free from concomitant immunosuppressive or immunomodulatory treatment (including interferon beta \\[IFNβ\\] and chronic systemic corticosteroids) for the duration of the study.\n* Must have a baseline MRI, conducted within 35 calendar days prior to enrollment.\n\nKey Exclusion Criteria:\n\n* Diagnosis or history of neuromyelitis optica (NMO), e.g., a long spinal lesion extending over 3 or more vertebral bodies was detected, or the subject has a history of positive tests for anti-aquaporin-4 (anti-AQP4) antibodies.\n* The subject is considered by the Investigator to be immunocompromised, based on medical history, physical examination, laboratory testing, or prior immunosuppressive or immunomodulating treatment.\n* An MS exacerbation (relapse) within 30 days prior to enrollment or, in the opinion of the Investigator, the subject has not stabilized from a relapse prior to enrollment at Week 0.\n* History of malignancy.\n* Known history of, or positive test result for human immunodeficiency virus (HIV) infection.\n* Known history of or positive test result for hepatitis C virus or hepatitis B virus within the year prior to enrollment.\n* History of severe allergic or anaphylactic reactions or known drug hypersensitivity.\n* A clinically significant infectious illness within 30 days prior to enrollment.\n* Abnormal liver function test results at screening: alanine aminotransferase (ALT), or aspartate aminotransferase (AST) \\>2 times of the upper limit of normal (ULN) or bilirubin \\>1.5 times of the ULN during screening.\n* Previous treatment with natalizumab, any murine protein, or any other therapeutic monoclonal antibody.\n* Any prior treatment with any of the following medications: total lymphoid irradiation, cladribine, T-cell or T-cell receptor vaccination.\n* Treatment with immunosuppressant medications, e.g., azathioprine, cyclophosphamide, methotrexate, and fingolimod within 6 months prior to enrollment, or mitoxantrone and cyclosporine within 12 months prior to enrollment.\n* Treatment with any of the following medications or procedures within 6 months prior to enrollment: intravenous immunoglobulin (IVIg), plasmapheresis, or cytapheresis.\n* Treatment with immunomodulatory medications (including IFNβ and glatiramer acetate \\[GA\\]) within 2 weeks of enrollment.\n* Treatment with any of the following medications within 30 days of enrollment: intravenous corticosteroid treatment, systemic corticosteroid treatment, 4-aminopyridine or related products.\n* Participation in any other investigational treatment within the 6 months prior to enrollment or concurrent with this study.\n\nPart B\n\nKey Inclusion Criteria:\n\n* Must give written informed consent and any authorizations required by local law.\n* Must have a diagnosis of relapsing-remitting MS, as defined by the revised McDonald criteria 1 through 4 (Polman et al, 2005). All other possible neurologic diagnoses must have been reasonably excluded by means of laboratory and/or imaging studies, in the opinion of the Investigator.\n* Japanese men and women aged 18 to 65, inclusive, at the time of informed consent.\n* All male subjects and female subjects of childbearing potential must practice effective contraception during the study and be able to continue contraception for 12 weeks after their last dose of study treatment.\n* Must have an EDSS score between 0.0 and 5.5, inclusive.\n* Must have experienced at least 1 medically documented clinical exacerbation within 12 months of enrollment.\n* Must be willing to remain free from concomitant immunosuppressive or immunomodulatory treatment (including IFNβ and chronic systemic corticosteroids) for the duration of the study.\n* Prior to enrollment all subjects must have: a screening MRI, or documentation of an MRI within the subject's medical record within 1 year of the screening visit, which reveals 3 or more T2 hyperintense lesions consistent with MS, and a baseline MRI, conducted within 7 calendar days prior to enrollment, which reveals at least 1 MRI lesion consistent with MS.\n\nKey Exclusion Criteria\n\n* Diagnosis or history of NMO, e.g., a long spinal lesion extending over 3 or more vertebral bodies was detected, or the subject has a history of positive tests for anti-AQP4 antibodies.\n* The subject is considered by the Investigator to be immunocompromised, based on medical history, physical examination, laboratory testing, or prior immunosuppressive or immunomodulating treatment.\n* An MS exacerbation (relapse) within 30 days prior to enrollment or, in the opinion of the Investigator, the subject has not stabilized from a relapse prior to enrollment at Week 0.\n* History of malignancy.\n* Known history, or positive test result of HIV infection.\n* Known history of or positive test result for hepatitis C virus or hepatitis B virus within the year prior to Enrollment.\n* History of severe allergic or anaphylactic reactions or known drug hypersensitivity.\n* A clinically significant infectious illness within 30 days prior to Enrollment.\n* Abnormal liver function test results at screening: ALT or AST \\>2 times of the ULN or bilirubin \\>1.5 times of the ULN during screening.\n* Previous treatment with natalizumab, any murine protein, or any other therapeutic monoclonal antibody.\n* Any prior treatment with any of the following medications: total lymphoid irradiation, cladribine, T-cell or T-cell receptor vaccination.\n* Treatment with immunosuppressant medications, e.g., azathioprine, cyclophosphamide, methotrexate, and fingolimod within 6 months prior to enrollment, or mitoxantrone and cyclosporine within 12 months prior to enrollment.\n* Treatment with any of the following medications or procedures within 6 months prior to enrollment: IVIg, plasmapheresis, or cytapheresis.\n* Treatment with immunomodulatory medications (including IFNβ and GA) within 2 weeks of enrollment.\n* Treatment with any of the following medications within 30 days of enrollment: intravenous corticosteroid treatment, systemic corticosteroid treatment, 4-aminopyridine or related products.\n* Participation in any other investigational treatment within the 6 months prior to enrollment or concurrent with this study.\n\nNOTE: Other protocol defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Number of Participants With Adverse Events (AEs)","description":"AE=any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. Serious AE (SAE)=any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, was a life threatening event; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; or any other medically important event that, in the opinion of the Investigator, may have jeopardized the participant or may have required intervention to prevent one of the other outcomes listed in the definition above. Events were categorized as related or not related; severity was categorized as mild, moderate, or severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Part B: Rate of Development of New Active Lesions Over 24 Weeks","description":"New active lesions were the sum of the gadolinium-enhancing (Gd+) lesions and any new or newly enlarging T2 hyperintense lesions that did not enhance as seen on cranial magnetic resonance imaging (MRI) scans. The rate is calculated for each participant as the ordinary least squares slope of the cumulative new active lesions over time.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.352","spread":"0.5648"},{"groupId":"OG001","value":"0.058","spread":"0.0748"}]}]}]},{"type":"SECONDARY","title":"Part B: Cumulative Number of New Active Lesions Over 24 Weeks","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"13.35"},{"groupId":"OG001","value":"1.5","spread":"2.06"}]}]}]},{"type":"SECONDARY","title":"Part B: Adjusted Annualized Relapse Rate Over 24 Weeks","description":"The frequency of clinical exacerbations over 24 weeks was assessed using an annualized relapse rate that was calculated for each treatment group as the total number of relapses experienced in the group over the 24 weeks of treatment, divided by the total number of subject-years followed in the study. Obtained from a Poisson regression model, adjusted for the baseline relapse rate.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.727","spread":null},{"groupId":"OG001","value":"0.532","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Cumulative Number of Gd+ Lesions Over 24 Weeks","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":"12.15"},{"groupId":"OG001","value":"1.2","spread":"1.68"}]}]}]},{"type":"SECONDARY","title":"Part B: Cumulative Number Of New Or Newly Enlarging, Non-Enhancing T2-Hyperintense Lesions Over 24 Weeks","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.84"},{"groupId":"OG001","value":"0.3","spread":"0.91"}]}]}]},{"type":"SECONDARY","title":"Part B: Number of Participants Who Were Relapse Free Over 24 Weeks","description":"Participants were categorized as relapse free=yes, relapse free=no, or relapse free=unknown. The category of relapse free=unknown includes participants who withdrew from the study and did not experience a relapse prior to withdrawal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Change From Baseline to Weeks 12 and 24 in the Global Assessment of Well-Being As Assessed by Participants Using a Visual Analog Scale (VAS)","description":"The participant's self-rating of global impression of his/her well-being was assessed with a VAS. The instrument ranged from 0 to 100 (mm), where a score of 0 denoted 'poor' and a score of 100 denoted 'excellent.'","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.5","spread":"23.66"},{"groupId":"OG001","value":"69.6","spread":"20.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"24.89"},{"groupId":"OG001","value":"-5.3","spread":"21.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"25.20"},{"groupId":"OG001","value":"-4.8","spread":"17.40"}]}]}]},{"type":"SECONDARY","title":"Part A: Concentration of Natalizumab in Serum","description":"The concentration of BG00002 in serum was determined using an Enzyme Linked Immunosorbent Assay (ELISA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119.4550","spread":"18.86145"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111.8159","spread":"18.35129"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.5707","spread":"26.17036"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.5144","spread":"18.26611"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.2038","spread":"17.02067"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3874","spread":"16.49046"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2363","spread":"12.02968"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.9994","spread":"11.45474"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5702","spread":"9.55131"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7048","spread":"15.50352"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.9105","spread":"16.06085"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.9645","spread":"16.41578"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.2724","spread":"14.51395"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145.5353","spread":"38.26877"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137.6666","spread":"30.47429"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"130.8829","spread":"30.17375"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120.0772","spread":"28.68860"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"103.3549","spread":"26.94133"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.2563","spread":"24.70785"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.7307","spread":"24.60531"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4002","spread":"21.41919"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.8368","spread":"16.33283"}]}]}]},{"type":"SECONDARY","title":"Part B: Concentration of Natalizumab in Serum","description":"The concentration of BG00002 in serum was determined using an Enzyme Linked Immunosorbent Assay (ELISA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.6475","spread":"14.68246"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4830","spread":"22.53573"}]}]}]},{"type":"SECONDARY","title":"Part A: Pharmacokinetic (PK) Profile of Natalizumab in Serum: Cmax","description":"Observed maximum concentration (Cmax) was calculated using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"144.36","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Pharmacokinetic (PK) Profile of Natalizumab in Serum: AUC(0-last) and (0-AUC∞)","description":"Area under the curve to the last measurable concentration (AUC\\[0-last\\]); and area under the curve extrapolated to infinity (0-AUC∞) were calculated using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31574.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46094.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43172.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Pharmacokinetic (PK) Profile of Natalizumab in Serum: Tmax and T1/2","description":"Time to maximum concentration (Tmax) and half-life (T1/2) were calculated using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"344.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"381.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Pharmacokinetic (PK) Profile of Natalizumab in Serum: Vd","description":"Volume of distribution (Vd) was calculated using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.422","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.561","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Pharmacokinetic (PK) Profile of Natalizumab in Serum: CL","description":"Systemic clearance (CL) was calculated using non-compartmental methods.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9497","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Status of Serum Antibodies to Natalizumab","description":"Persistent positivity is defined as 2 positive results separated by at least 6 to 12 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Number of Participants With Adverse Events (AEs)","description":"AE=any untoward medical occurrence that did not necessarily have a causal relationship with this treatment. Serious AE (SAE)=any untoward medical occurrence that at any dose: resulted in death; in the view of the Investigator, was a life threatening event; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in a congenital anomaly/birth defect; or any other medically important event that, in the opinion of the Investigator, may have jeopardized the participant or may have required intervention to prevent one of the other outcomes listed in the definition above. Events were categorized as related or not related; severity was categorized as mild, moderate, or severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Natalizumab Binding Saturation Of α4 Integrin Sites On Peripheral Blood Mononuclear Cells (PBMC)","description":"Pharmacodynamic activity was assessed by measuring the degree of saturation by BG00002 of the very late antigen-4 (VLA-4, also known as α4β1 integrin) receptor on peripheral blood mononuclear cell populations. This was accomplished by staining cells with phycoerythrin-conjugated anti-human immunoglobulin G4 (IgG4) antibody (hIgG4-PE) to label the cell-bound BG00002, followed by flow cytometric detection and quantification.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.282","spread":"1.6450"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.371","spread":"4.6811"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85.491","spread":"7.1019"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.929","spread":"6.8396"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.362","spread":"6.8992"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.742","spread":"7.3283"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.057","spread":"20.2412"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.615","spread":"22.0351"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.485","spread":"4.4088"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.314","spread":"7.1022"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.859","spread":"5.0230"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.575","spread":"5.9416"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.376","spread":"5.4459"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.842","spread":"5.5828"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.897","spread":"4.5757"}]}]}]},{"type":"SECONDARY","title":"Part A: Summary of Lymphocyte Counts Over Time","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1708.3","spread":"556.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1775.0","spread":"534.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3016.7","spread":"845.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3018.2","spread":"1112.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3340.0","spread":"939.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1550.0","spread":"70.71"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":12},"commonTop":["Multiple Sclerosis Relapse","Nasopharyngitis","Pharyngitis","Eczema","Insomnia"]}}}